Society of Nuclear Medicine and Molecular Imaging (SNMMI) | Strategic Alliance Partners
Latest from Society of Nuclear Medicine and Molecular Imaging (SNMMI)
89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
3
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
4
Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up
5
